Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Phase 2 Study to See if Simtuzumab (GS-6624) is Safe and Works in Idiopathic Pulmonary Fibrosis (IPF)

Study:

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Rationale:

n/a

Purpose:

The purpose of this study is to determine if Simtuzumab (GS-6624) is safe and effective in treating Idiopathic Pulmonary Fibrosis

Study Status: Recruiting

Recruiting:
Calvin Killingbeck 954-659-6247 killinc@ccf.org

Ron Wehrmann 216-445-0574 wehrmar@ccf.org

Condition Intervention Phase
Idiopathic Pulmonary Fibrosis Drug: Simtuzumab (GS-6624)
Drug: Placebo
Phase 2

Verified by Gilead Sciences January, 2014

Sponsored by: Gilead Sciences
Information provided by: Gilead Sciences
ClinicalTrials.gov identifier: NCT01769196

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Cleveland Clinic Florida
Weston, Florida 33331
United States

Cleveland Clinic
Cleveland, Ohio 44195
United States

Ganesh Raghu, MD, FCCP, FACP., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site